

1 **Article type:** Original article

2 **Title:**

3 **“Genomic and phenotypic characterization of Investigator Global Assessment (IGA) scale**
4 **based endotypes in atopic dermatitis”**

5 Sandra P Smieszek¹, Bart Przychodzen¹, Sarah E Welsh¹, Jennifer Brzezynski¹, Alyssa Kaden¹,
6 Michael Mohrman¹, Jim Wang¹, Changfu Xiao, Christos Polymeropoulos¹, Gunther Birznieks¹,
7 Mihael H Polymeropoulos¹

8 ¹ Vanda Pharmaceuticals, 2200 Pennsylvania NW, Suite 300-E, Washington, DC 20037

9 Twitter handle: @vandapharma

10

11 **Corresponding author:**

12 Sandra P. Smieszek
13 2200 Pennsylvania NW, Suite 300-E
14 Washington, DC 20037
15 Email: sandra.smieszek@vandapharma.com

16

17 **Funding sources:** Vanda Pharmaceuticals

18

19 **Conflicts of Interest:** SPS is an employee of Vanda and a stockholder. BPP is an employee of
20 Vanda and a stockholder. SEW is an employee of Vanda and a stockholder. JB is an employee
21 of Vanda and a stockholder. AK is an employee of Vanda and a stockholder. MM is an employee
22 of Vanda and a stockholder. CX is an employee of Vanda and a stockholder. CP is an employee
23 of Vanda and a stockholder. GB is an employee of Vanda and a stockholder. MHP is Chief
24 Executive Officer of Vanda.

25

26 IRB approval status: Reviewed and approved by Advarra IRB; Pro00025510

27

28 Clinicaltrials.gov listing: NCT03568331

29

30

31 **Keywords:** Atopic dermatitis; itch; endotypes; whole genome sequencing; cytokines

32

33

34 **ABSTRACT limited to 200 words**

35 *Background:* Atopic dermatitis (AD) is a heritable and heterogeneous inflammatory chronic skin
36 disorder. Utilizing decision tree/ supervised learning of extensive clinical, molecular and genetic
37 data, we aimed to define distinct AD endotypes.

38 *Methods:* Deep phenotyping and whole-genome sequencing was performed on samples obtained
39 from participants of EPIONE, a phase III study in AD patients with severe pruritus: mild (23%)
40 to moderate (64%) and severe (13%) as determined by validated Investigator Global Assessment
41 scale for Atopic dermatitis (vIGA-ADTM). Three categories of analysis were performed: clinical
42 associations, lab value associations (EOS, IgE, cytokines) and genetic analysis of whole-genome
43 sequencing data

44 *Results:*Based on a decision tree, we found that mild AD presents with fewer lesions with mild
45 erythema and minimal induration/papulation or oozing/crusting. In contrast, severe AD presents
46 with a larger number of erythematous lesions associated with significant induration/papulation or
47 oozing/crusting. We observe a significant differences between severity and eosinophil counts (p
48 < 0.001), IgE ($p < 0.001$) and *Filaggrin* (*FLG*) LOF frequency (OR 2.3 CI 1.6-3.2 $p < 0.0001$) as
49 well as interleukin pathway genes, specifically IL5RA variants differentiating the groups.

50 *Conclusion:* Our results suggest significant differences between severity groups across a number
51 of features appear to constitute distinct endotypes with likely distinct causative factors. Differing
52 underlying pathophysiology's indicate endotype knowledge is critical to help guide therapeutic
53 approaches to AD.

54

55 **Capsule summary** [cannot exceed 50 words]

- 56 • AD is a heritable and heterogeneous skin disorder that makes the ‘one size fits all’
57 therapeutic approach suboptimal for patients with AD.
- 58 • We attempted to define AD endotypes based on clinical, molecular, and genetic
59 characteristics. Clinical, CBC, and genetic associations all tend to suggest existence of
60 separate endotypes.

61 Introduction

62 Atopic dermatitis (AD) is a complex and heterogeneous, highly heritable, chronic, inflammatory
63 skin disorder. AD affects 7.3% of US adults^{1, 2}. The genetic background of AD is complex and
64 likely composed of a mixture of rare and common variants. The heritability of AD is estimated to
65 be around 75%². Studies have shown that there are genetic factors specific to AD beyond those
66 for general atopy^{3,4}. AD is manifested by a wide range of symptoms and significantly impacts
67 quality of life. Flares are usually characterized by extreme pruritus of red, rough, flaky and often
68 fissured regions of the skin, that over time thicken². Chronic pruritus, lasting more than 6 weeks,
69 is a key feature associated with AD. The extent of skin lesions and other physical symptoms vary
70 within this patient population and can be diagnosed as mild, moderate, or severe as defined by
71 the Investigator Global Assessment scale for Atopic Dermatitis (vIGA-ADTM). The etiology is
72 likely resultant from an interaction between the genetically determined skin barrier, immune
73 system dysregulation, and the environmental triggers².

74 One of the main functions of the skin is to act as a barrier between the individual and the
75 environment, preventing water loss and at the same time preventing pathogen and allergen
76 entry⁵. Skin barrier dysfunction is a key clinical feature of AD, as this facilitates penetration of
77 allergens, immunological dysfunction, and consequently an increased risk of developing
78 eczema^{5,6}. The skin barrier dysfunction has been associated with the etiology of the itch-scratch
79 cycle⁷. In addition, genes encoding skin barrier proteins have been shown to play a role in the
80 heritability of AD^{8,9}. Loss-of-function (LOF) variants resulting in aberrant *FLG* production,
81 constitute the best-known AD gene-association and have been shown to predispose individuals to
82 AD^{10,11}. Individuals harboring *FLG* LOF variants manifest clinical features such as dry and
83 fissured skin. LOF variants in *FLG* are associated with lower levels of natural moisturizing
84 factors (NMF) in AD¹². Additional genes involved in skin barrier function, including epidermal
85 differentiation complex (EDC) proteins, are thought to have a potential role in AD. The EDC
86 encodes proteins critical to the proper development of keratinocytes and normal formation of the
87 skin barrier¹³. Downregulation of EDC genes has also been implicated in AD^{14,15,16,17}.

88 Disrupted skin barrier promotes penetration of allergens, immunological dysfunction, and
89 consequently an increased risk of developing eczema¹⁸. Critical features of the TH2 immune
90 response include local production of TH2 cytokines activation of eosinophils (EOS) and mast
91 cells, as well as production of IgE¹⁹. Ultimately T-cell subsets, including Th2/Th22 cells, are
92 upregulated in AD skin²⁰. Interestingly both lesional and nonlesional AD showed a highly
93 polyclonal T cell receptor pattern, insinuating the lasting presence of potentially pathogenic
94 memory T cells beyond clinically inflamed lesions²⁰. Ultimately dysregulation leads to increased
95 production of neuropeptides such as substance P (SP) released from primary sensory nerves in
96 the skin²¹. SP binds the neurokinin-1 receptor (NK1R) and MRGPRs²². Elevated SP levels have
97 been observed in the blood and lesional skin of AD patients, and have been correlated with itch
98 intensity, as shown in challenge studies and further reiterated in transcriptome analysis^{23,7}.
99 Elevated SP levels further elicit vasodilation of short duration leading to mast cell degranulation,
100 nerve growth factor expression in keratinocytes, and neurogenic inflammation associated with
101 erythema and pruritus²¹. Proof of concept studies have shown increases in itch resulting from
102 injected SP and expression of NK1R in keratinocytes, as well as reduction in itch resulting from
103 inhibition of NK1R. Pruritus, perpetuates scratching that further damages the skin barrier⁷.

104 Our work aimed to evaluate the effect of clinical manifestations, molecular levels and genetic
105 associations and cytokine levels to further understand the architecture and variability of AD as

106 assessed in subjects during baseline visit. We aim to discern whether degree of severity
107 recapitulates individual endotypes in AD.

108 **Results**

109
110 EPIONE, a multi-center, placebo-controlled, double-blind study, enrolled and randomly assigned
111 (1:1) 341 patients aged 18 to 70 with AD Welsh et al., 2020 (manuscript under review) describes
112 the efficacy and safety results from EPIONE. At baseline, participants presented with a range of
113 disease severities from mild (23%) to moderate (64%), and severe (13%). Severity was defined
114 by Investigator Global Assessment scale for Atopic Dermatitis (vIGA-ADTM). For analysis, mild
115 AD as IGA scores of 1 (1) or 2 (77) at baseline, while more severe AD was defined as IGA
116 scores of 3 (218) or 4 (33). In addition to deep phenotyping we obtained AD samples for whole
117 genome sequencing (n=765 entire study population, n=332 randomized patients). **Table 1** shows
118 demographic and clinical characteristics of the studied cohort at baseline. **Figure 1** depicts the
119 baseline clinical and lab measurements across IGA groups. We examine each sub-component in
120 depth in the sections that follow.

121 **Clinical Association**

122 We collected extensive clinical information using the SCORAD index including total area
123 involved, intensity, and subjective measurements^{24, 25}. Canonically, we observe that mild AD
124 presents with fewer lesions, mild erythema, and minimal induration/papulation or
125 oozing/crusting. In contrast, severe AD presents with a larger number of erythematous lesions
126 associated with significant induration/papulation, oozing/crusting. Importantly, we observed that
127 the interaction between three most informative variables (Edema/Papules, Erythema and Total
128 Area Affected) can classify patients by disease severity. The most severe patients present almost
129 exclusively with highest SCORAD Edema/Papules score (3 on a 0-3 scale) or SCORAD
130 Erythema (3 on a 0-3 scale). Utilizing only those two variables we can accurately identify 35.8%
131 of IGA3/4 with only 2.5% of IGA1/2 falling into that category (**Figure 2A-B**). Remaining 64.2%
132 of IGA3/4 patients are more difficult to distinguish from IGA1/2. There is a clear separation of
133 the remaining IGA3/4 patients by the SCORAD Total Affected Area (**Figure 2C**).

134 We performed a series of classification and regression analyses to understand the underlying
135 nature of the severity subgroups utilizing multiple clinical variables at once. We focus our
136 analysis using classification trees. Based on a series of five clinical features from the SCORAD
137 scale, we were able to accurately differentiate between IGA 1/2 versus IGA 3/4. We obtained a
138 robust classification using SCORAD Total Affected Area (%), Edema/Papules, Erythema,
139 Lichenification, and Excoriation. Five-fold cross-validation classification (J48) yields weighted
140 83.8% precision and 80.1% recall and a large AUC 0.830. **Supplementary Figure 1** displays the
141 actual tree (J48) revealing the cutoffs and splits.

142 **Eosinophils and IgE**

143 Motivated by the hypothesis that atopy is key in the expression of AD, we evaluated the role of
144 counts of eosinophils and levels of IgE and their association with the clinical expression of AD.
145 We evaluated lab values (EOS, IgE, systemic cytokines) that may differentiate milder from more
146 severe AD. We detect a significant association between IGA and EOS levels. We have shown
147 that more severe AD (IGA3/4) is associated with significantly higher counts of eosinophils as

148 compared to milder AD (IGA1/2) (**Figure 1**), an effect that is significant (Mann-Whitney p-
149 value < 0.01). The effect is persistent in an extended screening cohort of 765 samples. Moreover
150 there is a significant difference between IGA 3 and 4 in the EOS levels (p-value < 0.0008) and
151 1/2 vs. 4 (p < 0.0001). This suggests that systemic eosinophil levels are increasingly correlated
152 across the IGA severity scale. All but 3 cases of the 32 cases above 0.5 are moderate to severe
153 AD subjects (29/282 of IGA3/4 and only 3/79 IGA1/2). Additionally, we report a significant
154 difference in distribution of patients with elevated serum IgE (**Figure 1D**, level > 100 IU/mL p-
155 value < 0.001).

156 **Genetic landscape of AD endotypes**

157 We performed whole genome sequencing of the entire study population (n=765). We
158 investigated the incidence of all *FLG* LOF variants in the genomes of the EPIONE study
159 patients, and compared them with the whole genome sequences of a control population (n=316).
160 of healthy volunteers as well as individuals from gnomAD database. More severe AD is
161 associated with a higher prevalence of *FLG* LOF variants (p value < 0.0001, OR 2.3 CI 1.6-3.2).
162 This is significant enrichment as compared to milder (p-value = 0.99, OR = 0.89 CI = 0.3-2.0).
163 Milder AD has incidence of LOF *FLG* variants comparable to normal population as defined by
164 gnomAD and an internal set of controls (IGA1/2: 6.4%, Vanda Controls: 6.2%, GnomAD: 8.4%)
165 whereas the moderate to severe subgroup has an elevated frequency of LOF *FLG* variants
166 (IGA3/4: 17.7%). This is contrary to the general observation that AD cases have higher
167 prevalence of *FLG* mutations than the control population, as this effect seems to be specific to
168 IGA3/4 subjects. The variants detected are depicted on **Figure 3** which displays the location of
169 individual LOF variants in both endotypes. We have now showed that the increased frequency
170 can be ascribed to the severe AD subtypes. The results are consistent for EDC gene
171 variants. Furthermore, we detect higher frequency if individuals with two or more *FLG* mutations
172 in the severe group as well as incidence of cases with CNV within the *FLG* gene present in the
173 IGA3/4. The allelic frequency of the two prevalent *FLG* LOF variants, p.R501* and p.S761fs as
174 well as the OR is displayed on panel B of **Figure 3**.

175 ***IL5RA* gene rare variants differentiate between IGA subgroups**

176 We have performed *in silico* interleukin (IL) screen using gene-centric collapsing analysis on a
177 pathway of IL genes as defined by GO terms, comprised of 96 genes. In a rare variant analysis
178 we obtain a significant result after conservative multiple hypothesis testing in *IL5RA* as
179 differentiating between the two severity groups). Direction of effect is consistent with a higher
180 EOS levels observed in IGA3/4. Binding of IL-5 to the α -subunit of the *IL5Ra* promotes the
181 heterodimerization of α and β subunits. As a result, many signal transduction pathways
182 are activated, including JAK/STAT modules, MAPK, Pi3K, and NF- κ B. The stimulation of these
183 kinases and TFs drives the expression of key genes responsible for differentiation, survival,
184 degranulation, adhesion, and recruitment of eosinophils. Furthermore through whole genome
185 sequence analysis we have also discovered that polymorphisms in the *IL5Ra* gene are associated
186 with higher count of eosinophils in this population of AD patients. The *IL5Ra* rare variant
187 rs200005614 associates with significantly higher level of EOS consistent with the effect
188 observed. Previously other variants were found to be associated with EOS such as *IL5RA*
189 *c.*-509IG>A which was shown to be associated with eosinophil count. *IL5RA* plays an
190 important role in coordinating the release of eosinophil and IgE production against antigens

191 leading to the development of atopy. The association of the IL5RA variants with the blood
192 eosinophil counts and the severe IGA) indicates that the IL5RA gene has a role for controlling
193 crucial role in eosinophil responses.

194 Cytokines

195 We measured a panel of systemic cytokines collected at baseline. We evaluated which cytokines
196 at baseline are above the normal ranges (as defined by clinical standards²⁶ and show the results
197 on a heatmap of ratios to reference range. This is displayed on **Figure 4** (log₂ ratio of cytokine to
198 a maximum value reported in reference range, red being above threshold levels levels). The
199 observed trends are suggestive of elevated levels of Th2 (IL-4, IL-5, and IL-13). Increased IL-5,
200 as well as IL-4 and IL-23 form a distinct, predominant group of patients (**Figure 4**).

201 Interestingly, there is a subgroup of patients that also have elevated IL-6, IL-8, and IL-13 (blue
202 ribbon highlight on **Figure 4**). IL-5 is produced by type 2 T helper cells and mast cells. It
203 stimulates B cell growth and increases immunoglobulin secretion, and primarily is the key
204 mediator of eosinophil activation. Its high expression has been previously associated with
205 chronic AD. It stimulates activated B cell and T cell proliferation, and differentiation of B cells
206 into plasma cells. IL-4 has been implicated in tissue inflammation and epidermal barrier
207 dysfunction²⁷. These patients have decreased IFN-gamma and IL-12 levels across all patients,
208 not limited to patients with elevated Th2. Whereas the main signature pattern (elevated IL-4, IL-
209 5, and IL-23) is still as abundant in IGAs 1/2 and even 3s, subjects defined as 4 lack a subgroup
210 of patients with high level of IL-6, IL-8, and IL-13. **Figure 5**, displays the cytokine levels in IGA
211 subgroups. There is a distinct group of patients across all IGA severities that has low systemic
212 levels of all cytokines. In addition many more severe outliers have several magnitude higher
213 levels across the entire cytokine panel as compared to milder cases.

214 Discussion

215 Defining AD subtypes has been a debated subject in the field. Definitions analogous to asthma
216 have been used based on elevated IgE: with presence ("extrinsic") or absence ("intrinsic") of
217 increased IgE²⁸. According to epidemiological studies, mild AD is the most common type of AD,
218 affecting approximately 60% of AD cases (Atopic Dermatitis in America Study). The factors
219 underlying severity are not well understood. We present here clinical and genetic evidence
220 suggesting that AD may be composed of distinct endotypes. Clinical features suggest milder and
221 severe AD appear to be distinct entities that can be differentiated by five clinical features from
222 the SCORAD index. . More severe AD is associated with a higher prevalence of mutation burden
223 in the FLG skin barrier structural protein. Consistent with previous investigations, including a
224 study in Denmark on (n=470) patients with AD²⁹, as well as extensive studies of *FLG* gene⁵.

225 We have reported that more severe AD is associated with significantly higher count of
226 eosinophils as compared to milder AD. Eosinophils are mediators of the inflammatory response
227 and are responsible for recruiting other immune cells in the lesions. As such, it is likely that
228 severe pruritus associated with both mild and severe AD may have different mediators. Based on
229 our findings we hypothesize that the contribution of SP in mild AD, in generating and
230 transmitting the pruritic signal, may be relatively more significant than that seen in severe AD.
231 Through whole genome sequence analysis we have also discovered that polymorphisms in the
232 IL5Ra gene are associated with higher count of eosinophils in this population of AD patients.
233 The association between eosinophils and IL5RA has been previously reported in asthmatic

234 patients. Here we find the association by gene-centric testing between the two severity groups.
235 This is in agreement with a reported association of rs2522411 variant in the IL-5 gene which was
236 significantly associated with extrinsic AD³⁰. When evaluating IL genes we detect IL5RA rare
237 variants further differentiating between severities, with rare IL5RA variants accumulating in the
238 more severe cases.

239 The described findings lend credence to the existence of endotypes within AD that are
240 manifested clinically and are becoming more understood in terms of underlying mechanisms.
241 These findings may have implications for both diagnosis and treatment course of the disorder. As
242 seen in (Welsh et al. 2020, manuscript under review) a robust anti-pruritic effect was observed in
243 only the IGA1/2 population while the difference from placebo was not significant in the more
244 severe IGA population. Endotype analyses define the underlying clinical and genetic factors of
245 mild versus more severe AD, and would indicate that the immune response and skin barrier
246 dysfunction tends to be increased in more severe AD. This may mean treating such patients may
247 require more immunological therapies. In contrast, mild patients without such underlying factors
248 may be better served with direct targeted therapies such as an anti-pruritic agent addressing the
249 severe itch they may still experience despite their lesions being almost clear or mild. Further
250 attempts to define AD endotypes should be made to define the optimal therapeutic approach,
251 moving towards precision medicine-based treatment of AD based on clinical, molecular, and
252 genetic characteristics.

253 **Acknowledgements**

254 We are grateful to all the study participants and all whom made the study possible

255 **Figure legend**

256 **Figure 1.** Atopic dermatitis endotypes

257 **Figure 2.** Differences between mild and moderate to severe subtypes in terms of clinical feature
258 space

259 **Figure 3.** FLG LOF variants across IGA endotypes

260 **Figure 4.** Cytokine panel at baseline (ratio to reference range)

261 **Figure 5.** Individual cytokine scatter plots

262

263 **Table legend**

264 **Table 1.** Baseline demographic and clinical characteristics

	Overall
	N=341
Age, mean (SD)	41.6 (15.3)
Male, n (%)	118 (34.6)
Ethnic origin, n (%)	
White	228 (66.9)
Black	83 (24.3)
Asian	19 (5.6)
Other	11 (3.2)
BMI (kg/m ²)	28.2 (5.2)
WI-NRS	8.2 (1.3)
BSA	14.21 (17.2)
SCORAD	50.5 (14.5)
EASI	10.54 (10.4)
vIGA-AD, n (%)	
Almost Clear (1)	2 (0.6)
Mild (2)	77 (22.6)
Moderate (3)	218 (63.9)
Severe (4)	44 (12.9)
Eosinophil Count (10 ⁹ /L)	0.25 (0.2)
FLG LOF	51 (15.4)

IgE, n (% of ≥ 100 kU/L) 167 (49.0)


265

266 **References**

- 267 1. Chiesa Fuxench ZC, Block JK, Boguniewicz M, et al. Atopic Dermatitis in America
268 Study: A Cross-Sectional Study Examining the Prevalence and Disease Burden of Atopic
269 Dermatitis in the US Adult Population. *J Invest Dermatol.* 2019;139(3):583-590.
270 doi:10.1016/j.jid.2018.08.028
- 271 2. Stein SL, Cifu AS. Management of Atopic Dermatitis. *JAMA.* 2016;315(14):1510-1511.
272 doi:10.1001/JAMA.2016.1459
- 273 3. Dold S, Wjst M, von Mutius E, Reitmeir P, Stiepel E. Genetic risk for asthma, allergic
274 rhinitis, and atopic dermatitis. *Arch Dis Child.* 1992;67(8):1018-1022.
275 doi:10.1136/adc.67.8.1018
- 276 4. Barnes KC. An update on the genetics of atopic dermatitis: scratching the surface in 2009.
277 *J Allergy Clin Immunol.* 2010;125(1):16-29.e1-11; quiz 30-31.
278 doi:10.1016/j.jaci.2009.11.008
- 279 5. Chen H, Common JEA, Haines RL, et al. Wide spectrum of filaggrin-null mutations in
280 atopic dermatitis highlights differences between Singaporean Chinese and European
281 populations. *Br J Dermatol.* 2011;165(1):106-114. doi:10.1111/j.1365-2133.2011.10331.x
- 282 6. Gao P-S, Rafaels NM, Hand T, et al. Filaggrin mutations that confer risk of atopic
283 dermatitis confer greater risk for eczema herpeticum. *J Allergy Clin Immunol.*
284 2009;124(3):507-513, 513.e1-7. doi:10.1016/j.jaci.2009.07.034
- 285 7. Nattkemper LA, Tey HL, Valdes-Rodriguez R, et al. The Genetics of Chronic Itch: Gene
286 Expression in the Skin of Patients with Atopic Dermatitis and Psoriasis with Severe Itch. *J*
287 *Invest Dermatol.* 2018;138(6):1311-1317. doi:10.1016/j.jid.2017.12.029
- 288 8. Czarnowicki T, Krueger JG, Guttman-Yassky E. Skin Barrier and Immune Dysregulation
289 in Atopic Dermatitis: An Evolving Story with Important Clinical Implications. *J Allergy*
290 *Clin Immunol Pract.* 2014;2(4):371-379. doi:10.1016/J.JAIP.2014.03.006
- 291 9. Bin L, Leung DYM. Genetic and epigenetic studies of atopic dermatitis. *Allergy, Asthma*
292 *Clin Immunol.* 2016;12(1):52. doi:10.1186/s13223-016-0158-5
- 293 10. Margolis DJ, Apter AJ, Gupta J, et al. The persistence of atopic dermatitis and filaggrin
294 (FLG) mutations in a US longitudinal cohort. *J Allergy Clin Immunol.* 2012;130(4):912-
295 917. doi:10.1016/j.jaci.2012.07.008
- 296 11. Smieszek SP, Welsh S, Xiao C, et al. Correlation of age-of-onset of Atopic Dermatitis
297 with Filaggrin loss-of-function variant status. 2020:1-11. doi:10.1038/s41598-020-59627-
298 7
- 299 12. Engebretsen KA, Bandier J, Kezic S, et al. Concentration of filaggrin monomers, its
300 metabolites and corneocyte surface texture in individuals with a history of atopic
301 dermatitis and controls. *J Eur Acad Dermatology Venereol.* 2018;32(5):796-804.
302 doi:10.1111/jdv.14801
- 303 13. Mischke D, Korge BP, Marenholz I, Volz A, Ziegler A. *Genes Encoding Structural*
304 *Proteins of Epidermal Cornification and S100 Calcium-Binding Proteins Form a Gene*
305 *Complex ("Epidermal Differentiation Complex") on Human Chromosome*
306 *Lq21.* Vol 106.; 1996. doi:10.1111/1523-1747.ep12338501
- 307 14. Kyriiotou M, Huber M, Hohl D. The human epidermal differentiation complex: cornified
308 envelope precursors, S100 proteins and the ‘fused genes’ family. *Exp Dermatol.*
309 2012;21(9):643-649. doi:10.1111/j.1600-0625.2012.01472.x
- 310 15. Guttman-Yassky E, Suárez-Fariñas M, Chiricozzi A, et al. Broad defects in epidermal

- 311 cornification in atopic dermatitis identified through genomic analysis. *J Allergy Clin*
312 *Immunol.* 2009;124(6):1235-1244.e58. doi:10.1016/j.jaci.2009.09.031
- 313 16. Jensen J-M, Fölster-Holst R, Baranowsky A, et al. Impaired Sphingomyelinase Activity
314 and Epidermal Differentiation in Atopic Dermatitis. *J Invest Dermatol.* 2004;122(6):1423-
315 1431. doi:10.1111/j.0022-202X.2004.22621.x
- 316 17. Sugiura H, Ebise H, Tazawa T, et al. Large-scale DNA microarray analysis of atopic skin
317 lesions shows overexpression of an epidermal differentiation gene cluster in the
318 alternative pathway and lack of protective gene expression in the cornified envelope. *Br J*
319 *Dermatol.* 2005;152(1):146-149. doi:10.1111/j.1365-2133.2005.06352.x
- 320 18. Sandilands A, Terron-Kwiatkowski A, Hull PR, et al. Comprehensive analysis of the gene
321 encoding filaggrin uncovers prevalent and rare mutations in ichthyosis vulgaris and atopic
322 eczema. *Nat Genet.* 2007;39(5):650-654. doi:10.1038/ng2020
- 323 19. McAleer MA, Irvine AD. The multifunctional role of filaggrin in allergic skin disease. *J*
324 *Allergy Clin Immunol.* 2013;131(2):280-291. doi:10.1016/j.jaci.2012.12.668
- 325 20. Brunner PM, Emerson RO, Tipton C, et al. Nonlesional atopic dermatitis skin shares
326 similar T-cell clones with lesional tissues. *Allergy.* 2017;72(12):2017-2025.
327 doi:10.1111/all.13223
- 328 21. Ständer S, Yosipovitch G. Substance P and neurokinin 1 receptor are new targets for the
329 treatment of chronic pruritus. *Br J Dermatol.* 2019;181(5):932-938.
330 doi:10.1111/bjd.18025
- 331 22. Azimi E, Reddy VB, Shade K-TC, et al. Dual action of neurokinin-1 antagonists on Mas-
332 related GPCRs. *JCI Insight.* 2016;1(16):e89362. doi:10.1172/jci.insight.89362
- 333 23. Teresiak-Mikołajczak E, Czarnecka-Operacz M, Jenerowicz D, Silny W. Neurogenic
334 markers of the inflammatory process in atopic dermatitis: relation to the severity and
335 pruritus. *Adv Dermatology Allergol.* 2013;5(5):286-292. doi:10.5114/pdia.2013.38357
- 336 24. Schmitt J, Spuls P, Boers M, et al. Towards global consensus on outcome measures for
337 atopic eczema research: results of the HOME II meeting. *Allergy.* 2012;67(9):1111-1117.
338 doi:10.1111/j.1398-9995.2012.02874.x
- 339 25. Severity Scoring of Atopic Dermatitis: The SCORAD Index. *Dermatology.*
340 1993;186(1):23-31. doi:10.1159/000247298
- 341 26. Kleiner G, Marcuzzi A, Zanin V, Monasta L, Zauli G. Cytokine levels in the serum of
342 healthy subjects. *Mediators Inflamm.* 2013;2013. doi:10.1155/2013/434010
- 343 27. Hänel KH, Cornelissen C, Lüscher B, Baron JM. Cytokines and the skin barrier. *Int J Mol*
344 *Sci.* 2013;14(4):6720-6745. doi:10.3390/ijms14046720
- 345 28. Karimkhani C, Silverberg JI, Dellavalle RP. Defining intrinsic vs. extrinsic atopic
346 dermatitis. *Dermatol Online J.* 2015;21(6).
- 347 29. Holm JG, Agner T, Clausen M-L, Thomsen SF. Determinants of disease severity among
348 patients with atopic dermatitis: association with components of the atopic march. *Arch*
349 *Dermatol Res.* 2019;311(3):173-182. doi:10.1007/s00403-019-01895-z
- 350 30. Namkung J-H, Lee J-E, Kim E, et al. IL-5 and IL-5 receptor alpha polymorphisms are
351 associated with atopic dermatitis in Koreans. *Allergy.* 2007;62(8):934-942.
352 doi:10.1111/j.1398-9995.2007.01445.x
- 353

Graphic Summary



Graphic Summary

- A. Distinct endotypes and clinical presentation of AD as defined by IGA 1 and 2 (mild) and IGA 3 and 4 (moderate and severe)
- B. Distribution of clinical variables across endotypes as defined by IGA 1 and 2 (mild) and IGA 3 and 4 (moderate and severe)
- C. Significant differences in Eosinophil counts across endotypes as defined by IGA 1 and 2 (mild) and IGA 3 and 4 (moderate and severe)

Figure 1






Figure 1 Hive plots of baseline clinical and lab values in association with severity as defined by IGA. Significant difference is displayed between IGA groups in A. SCORAD total score B. BSA C. Eosinophils (of particular interest are the cases > 0.5) D. IgE > 100 as marked by the red line. All significant results denoted by a */**/***.


A




B





C



D





FLG LOF's






Figure 3. Lollipop plots display the location and frequency of the identified variants in *Filaggrin*. We observe a significant enrichment of rare LOF variants in *FLG* detected in moderate and severe AD patients (IGA 3 and 4) as compared to mild AD (IGA 1 and 2).

Figure4

Blood Cytokine Panel
Ratio to reference range

medRxiv preprint doi: <https://doi.org/10.1101/2020.04.16.20058677>; this version posted April 20, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.






Figure 4b. Scatter plots of cytokine levels across IGA categories

Table 1. Baseline demographic and clinical characteristics

medRxiv preprint doi: <https://doi.org/10.1101/2020.04.16.20058677>; this version posted April 20, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.


	Overall N=341
Age, mean (SD)	41.6 (15.3)
Male, n (%)	118 (34.6)
Ethnic origin, n (%)	
White	228 (66.9)
Black	83 (24.3)
Asian	19 (5.6)
Other	11 (3.2)
BMI (kg/m ²)	28.2 (5.2)
Worst Itch- NRS	8.2 (1.3)
BSA	14.21 (17.2)
SCORAD	50.5 (14.5)
EASI	10.54 (10.4)
vIGA-AD, n (%)	
Almost Clear (1)	2 (0.6)
Mild (2)	77 (22.6)
Moderate (3)	218 (63.9)
Severe (4)	44 (12.9)
Eosinophil Count (10 ⁹ /L)	0.25 (0.2)
FLG LOF	51 (15.4)
IgE, n (% of >= 100 kU/L)	167 (49.0)

SUPPLEMENTARY MATERIAL

medRxiv preprint doi: <https://doi.org/10.1101/2020.04.16.20058677>; this version posted April 20, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

S. Figure 1 Decision Tree.


medRxiv preprint doi: <https://doi.org/10.1101/2020.04.16.20058677>; this version posted April 20, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



S2. IL5RA rare variants *in silico* IL panel (described not a figure)


medRxiv preprint doi: <https://doi.org/10.1101/2020.04.16.20058677>; this version posted April 20, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

rs200005614




S3 PCA of the WGS data

medRxiv preprint doi: <https://doi.org/10.1101/2020.04.16.20058677>; this version posted April 20, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



S4 IgE SCORAD and EOS

medRxiv preprint doi: <https://doi.org/10.1101/2020.04.16.20058677>; this version posted April 20, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.



S5 FLG S tables

medRxiv preprint doi: <https://doi.org/10.1101/2020.04.16.20058677>; this version posted April 20, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.

VARIANTS	IGA1+2			IGA3+4		
	P value	OR	CI	Pvalue	OR	CI
501X	0.6584	1.936	(0.994 to 3.769)	0.0588	1.4	(0.3404 to 0.649)
2284FS	0.4593	1.497	(0.472 to 4.750)	0.0042	2.3	(1.393 to 3.963)
LOF ALL	0.9999	0.8993	(0.391 to 2.069)	<0.0001	2.3	(1.683 to 3.208)

Below is the MAF table

	501	501	2284fs	LOF	rsSB_all
MAF	white	501	2284fs	LOF	rsSB_all
1and2	0.0212	0.0128	0.0192	0.0384	0.198
3and4	0.02	0.0177	0.0295	0.0885	0.216
GNOMAD	0.0163	0.009386	0.01314	0.0451	0.16